// App-Quantinova.ai

: BLINATUMOMAB + PONATINIB FOR RELAPSED PH1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE FRENCH EXPERIENCE.

Researchers

Presenter

  • Marie-Anne Couturier

Principal Investigators

  • Xavier Thomas

  • Emmanuel Raffoux

  • Franoise Huguet

  • Cline Berthon

  • Clestine Simand

  • Maria-Pilar Gallego-Hernanz

  • Yosr Hicheri

  • Mathilde Hunault-Berger

  • Colombe Saillard

  • Thibaut Leguay

  • Patrice Chevallier

Medical Centers

  • Hematology,Hôpital MORVAN, CHRU BREST,BREST,France

  • Hematology,Hopital Lyon Sud,Lyon,France

  • Hematology,APHP Saint-Louis,PARIS,France

  • Hematology,Institut Universitaire de Cancer Toulouse - Oncopole,TOULOUSE,France

  • Hematology, CHRU Lille Hopital Claude Huriez, Lille, Lille, France

  • Hematology,CHU de Hautepierre, Strasbourg,STRASBOURG,France

  • Hematology,CHU La Miletrie, Poitiers,POITIERS,France

  • Hematology,Hôpital Saint Eloi, CHRU Montpellier,MONTPELLIER,France

  • hematology,CHU Angers,ANGERS,France

  • Hematology,Institut Paoli-Calmettes,MARSEILLE,France

  • Hematology,Hôpital Haut-Leveque, CHU Bordeaux,BORDEAUX,France

  • Hematology,Hotel Dieu, CHU Nantes,NANTES,France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

  • Ponatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved